Samsung Bioepis Eyes US Trastuzumab Potential As It Hits Profitability
Firm Recently Entered Crowded US Trastuzumab Market With Ontruzant
In an exclusive interview, the executive vice-president for Samsung Bioepis’ commercial division, Sang-Jin Pak, tells Generics Bulletin there is plenty of opportunity remaining in the crammed US trastuzumab market and explains what an achievement it was for the South Korea-based company to reach profitability only eight years after inception.
